Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease

Pulmonary Disease, Chronic Obstructive Clinical Trial

Official title:

Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law]) of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02232594
• Other study ID #: 215.1358
• Status: Completed
• Phase: N/A
• First received: September 4, 2014
• Last updated: September 4, 2014
• Start date: January 2000

Study information

• Verified date: September 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Observational

Clinical Trial Summary

The aim of this postmarketing surveillance is to obtain further information about the tolerability and efficacy of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice

Recruitment information / eligibility

• Status: Completed
• Enrollment: 834
• Est. primary completion date: December 2000
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Patients of either sex over 40 years with the symptoms of a chronic obstructive airways disease

• Only patients which have not been treated with Berodual® within the last year should be included

Exclusion Criteria:

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Berodual® metered-dose inhaler

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Chronic Disease
• Pulmonary Disease, Chronic Obstructive
• Respiratory Tract Diseases

Intervention

Drug:
• Berodual®

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall severity of the clinical picture rated on a 4- point scale		after 3 and 6 weeks	No
Secondary	Assessment of efficacy by investigator on a 4-point scale		after 3 and 6 weeks	No
Secondary	Assessment of efficacy by patient on a 4-point scale		after 3 and 6 weeks	No
Secondary	Assessment of tolerability by investigator on a 4-point scale		after 3 and 6 weeks	No
Secondary	Assessment of tolerability by patient on a 4-point scale		after 3 and 6 weeks	No
Secondary	Number of patients with adverse drug reactions		up to 6 weeks	No

External Links

•   Link